| Study Name | Description | Trial Category | Trial SubCategory |
|---|---|---|---|
| EA2183 | The purpose of this study is to determine if adding radiation to chemo is beneficial. You must be diagnosed with metastatic HER2 negative esophageal and gastric cancer. | Cancer | Esophageal |
| EA5182 | This study is comparing Osimertinib and Bevacizumab vs Osimertinib alone as first-line treatment for patients with metastatic EGFR mutant Non-Small Cell Lung Cancer (NSCLC). You must be diagnosed with stage 3 or 4 NSCLC. | Cancer | Non-Small Cell Lung |
| EAA173 | The purpose of this study is determine if dararumumab enhances the effectiveness of revlimid in patients with smoldering myeloma. You must be diagnosed with asymptomatic high risk smoldering multiple myeloma. | Cancer | Smoldering Myeloma |
| EAA181 | The purpose of this study is to determine what consolidation regimen is most effective. Patients cannot get stem cell transplant until first relapse or later. You must have newly diagnosed multiple myeloma (MM). | Cancer | Multiple Myeloma |
| EAY191 ComboMATCH | The purpose of this study is to find targeted therapy for specific gene mutations in metastatic or advanced cancer. You must have progressed on standard of care treatment or have a cancer which has no standard of care treatment. If select mutations are found you may be eligible for a sub-study. | Cancer | Genomics |
| EAY191-A6 ComboMATCH | The purpose of this study is to see if adding Binimetinib in combination with FOLFOX is more effective treatment. You must be diagnosed with biliary tract cancer with a MAPK pathway gene mutation. | Cancer | Biliary |
| EAY191-E4 ComboMATCH | The purpose of this study is to determine the effectiveness of nilotinib and paclitaxel in patients with prior taxane treated solid tumors. You must have had at least one prior line of therapy in the metastatic setting. | Cancer | Solid Tumors |
| EAY191-N2 ComboMATCH | This study is for people diagnosed with hormone receptor positive breast cancer that has spread. A NF1 gene mutation must exist. | Cancer | Metastatic Breast |
| EAY191-N4 | The purpose of this study is to compare Selumetinib and Olaparib vs Selumetinib alone. You must be diagnosed with recurrent or persisent Ovarian or Endometiral cancer. Your cancer must have a RAS pathway mutation. | Cancer | Ovarian & Endometrial |
| EAY191-S3 ComboMATCH | The purpose of this study is to determine the effectiveness of Paclitaxel and Ipatasertib in patients who progressed within 6 months of taxane-based therapy. You must have a a AKT-Altered cancer. You must have a locally advanced, unresectable or metastatic cancer. | Cancer | Solid Tumors (non-breast) |
| ISPY 2 | This study uses the type of breast cancer you are diagnosed with to determine what treatment you are given. You must be diagnosed with stage 2 or stage 3 breast cancer. This study requires regular MRI's. | Cancer | Breast |
| NRG-GI008 | The purpose of this study to use blood draws looking at the tumor DNA in the blood to determine need for chemotherapy. You must be diagnosed with stage 3 colon cancer. | Cancer | Colon |
| NRG-GU009 | The purpose of this study is to determine if it is effective to use your genomic risk to determine the level of treatment you need. Those with a lower genomic risk get a de-intensified treatment and those with a higher risk get a intensified treatment. You must be diagnosed with high-risk prostate cancer. | Cancer | Prostate |
| NRG-GU010 | The purpose of this study is to determine if it is effective to use your genomic risk to determine the level of treatment you need. Those with a lower genomic risk get a de-intensified treatment and those with a higher risk get a intensified treatment. You must be diagnosed with unfavorable intermediate risk prostate cancer. | Cancer | Prostate |
| NRG-LU008 | The purpose of this study is to compare chemo and radiation followed by immunotherapy vs SBRT (stereotactic body radiation therapy) to primary tumor follwed by chemo and radiation then immunotherapy. You must be diagnosed with Stage 2 or 3 non-small cell lung cancer (NSCLC). | Cancer | Non-Small Cell Lung |
| S1922 | The purpose of this study is to determine the effectiveness of Ramucirumab and Paclitaxel vs Folfiri chemo. You must be diagnosed with metastatic or unresectable small bowel cancer. | Cancer | Small Bowel |
| S2001 | The purpose of this study is to determine the effectiveness of Olaparib + Prembrolizumab vs Olaparib alone. You must be diagnosed with metastatic pancreatic cancer with a BRCA1 or BRCA2 mutation. | Cancer | Pancreatic |
| S2200 | The purpose of this study is to compare treatment using cabozantinib with or without atezolizmab. You must be diagnosed with metastatic papillary renal cell cancer. | Cancer | Metastatic Renal Cell |
| S2212 | The purpose of this study is to compare anthracycline-free, taxane-platinum chemo with pembrolizumab to taxane-platinum-anthracycline chemo with pembrolizumab. This study is for people diagnosed with triple negative breast cancer. | Cancer | Breast |
| URCC 18007 | A study see if Bupropion is effective for reducing cancer-related fatigue. You must have completed surgery, radiation and/or IV chemo at least 2 months prior to enrollment. | Cancer | All tumor types |
| A022101 | The purpose of this study is to evaluate radiation, ablation and surgery. You must be diagnosed with metastatic colorectal cancer. The primary tumor must be able to surgically resected. | Cancer | Colorectal |
| A022102 | The purpose of this study is to compare effectiveness of mFOLFIRINOX with or without nivolumab and mFOLFOX6 with or without nivolumab . You must have newly diagnosed metastatic HER2 negative gastroesophageal cancer. | Cancer | Esophageal |
| A022104 | The purpose of this study is to look at the effectiveness of two chemo regimens mFOLFOX6 or CAPOX vs mFOLFIRINOX in getting patients to remission. You must be diagnosed with stage 2 or 3 rectal cancer. | Cancer | Rectal |
| S1925 | The purpose of this study is to compare early intervention with Venetoclax and Obinutuzumab vs delayed therapy in newly diagnosed asymptomatic high0risk patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). You must have been diagnosed with CLL or SLL within the last 12 months. | Cancer | Hematology |
| A031803 | The purpose of this study is to determine the effectiveness of intravesical gemcitabine in combination with prembrolizumab. Patients must have been diagnosed with invasive bladder and already received chemo. | Cancer | Bladder |
| E4512 (sub study A151216) | The purpose of this study is to compare Crizotinib vs observation for patients with a ALK+ Fusion Protein to determine if Crizotinib use results in improved disease-free survival. You must be diagnosed with stage 1B, stage 2 or stage 3A resectable or completely resected non-small cell lung cancer (NSCLC). | Cancer | Non-Small Lung |
| EA3132 | This study is comparing radiation therapy with and without Cisplatin. You must have surgically resected squamous cell carcinoma of the head and neck stage 3 or 4. | Cancer | Head and Neck |
| EA3161 | This study is comparing maintenance Nivolumab vs observation in patients with locally advance, intermediate risk HPV Positive oropharynx cancer. | Cancer | Oropharyngeal |
| EA5163 | The purpose of this study is to evaluate overall survival using immunotherapy alone or in combination with chemotherapy in advanced non-squamous Non-Small Cell Lung Cancer (NSCLC). You must be diagnosed with stage 4 Non-Small Cell Lung Cancer (NSCLC). | Cancer | Non-Small Cell Lung |
| LUNGMAP | This is a screening study to eavluate biomarker-driven therapies and immunotherapies in previously treated Non-Small Cell Lung Cancer (NSCLC). You must be diagnosed with Stage 4 or recurrent NSCLC. Tissue is sent for screening and patient can be assigned to a sub study based on mutations found. | Cancer | Metastatic Non-Small Cell Lung |
Unsupported Browser! This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.